These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 11761963)

  • 1. [Intravenous ultrasound contrast agent, Levovist].
    Kudo M
    Nihon Rinsho; 2001 Oct; 59 Suppl 6():306-13. PubMed ID: 11761963
    [No Abstract]   [Full Text] [Related]  

  • 2. Color doppler ultrasound of liver lesions: signal enhancement after intravenous injection of the ultrasound contrast agent Levovist.
    Ernst H; Hahn EG; Balzer T; Schlief R; Heyder N
    J Clin Ultrasound; 1996 Jan; 24(1):31-5. PubMed ID: 8655665
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Sonographic depiction of woodchuck hepatomas using intravenously injected contrast agents].
    Nada T; Moriyasu F; Kono Y; Matsumura T
    Nihon Rinsho; 1998 Apr; 56(4):980-4. PubMed ID: 9577620
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of SH U 508 A (Levovist) in color Doppler ultrasonography of hepatocellular carcinoma vascularization.
    Angeli E; Carpanelli R; Crespi G; Zanello A; Sironi S; Del Maschio A
    Radiol Med; 1994 May; 87(5 Suppl 1):24-31. PubMed ID: 8209014
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Evaluation of blood flows inside hepatic tumors using color Doppler echography with galactose-based intravenous contrast medium "SH/TA 508" administration].
    Ishii M; Kawauchi A; Sakamoto M; Sasaki K; Kumano Y; Nishida H; Mukai T; Kusano M
    Nihon Rinsho; 1998 Apr; 56(4):975-9. PubMed ID: 9577619
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Usefulness of enhanced ultrasonography after administration of intravenous contrast agent in the evaluation of therapeutic effect in treatment of hepatocellular carcinoma, and efficacy of percutaneous ethanol injection therapy (PEIT) for residual tumor].
    Nishiharu T; Maeda N; Hara M; Yamashita Y
    Nihon Igaku Hoshasen Gakkai Zasshi; 2001 Dec; 61(14):790-5. PubMed ID: 11828757
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison between color power Doppler ultrasound with echo-enhancer and spiral computed tomography in the evaluation of hepatocellular carcinoma vascularization before and after ablation procedures.
    Cedrone A; Pompili M; Sallustio G; Lorenzelli GP; Gasbarrini G; Rapaccini GL
    Am J Gastroenterol; 2001 Jun; 96(6):1854-9. PubMed ID: 11419839
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatocellular carcinoma: contrast enhancement with Levovist.
    Choi BI; Kim AY; Lee JY; Kim KW; Lee KH; Kim TK; Han JK
    J Ultrasound Med; 2002 Jan; 21(1):77-84. PubMed ID: 11794406
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ultrasound contrast agent Levovist in colour Doppler sonography of hepatocellular carcinoma in Chinese patients.
    Khong PL; Chau MT; Fan ST; Leong LL
    Australas Radiol; 1999 May; 43(2):156-9. PubMed ID: 10901894
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Feasibility study of an ultrasound contrast agent (levovist) in color Doppler imaging of liver neoplasms.
    Jiang Y; Dai Q; Liu J; Zhang J; Chang X; Cai S; Tan L
    Chin Med Sci J; 1999 Sep; 14(3):167-9. PubMed ID: 12903818
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnosis of hepatocellular carcinoma using digital subtraction imaging with the contrast agent, Levovist: comparison with helical CT, digital subtraction angiography, and US angiography.
    Yamamoto K; Shiraki K; Deguchi M; Sugimoto K; Sakai T; Ohmori S; Murata K; Hashimoto A; Shimizu A; Okuda Y; Nakano T
    Oncol Rep; 2002; 9(4):789-92. PubMed ID: 12066210
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatocellular carcinoma: harmonic ultrasound and contrast agent.
    Kim TK; Kim AY; Choi BI
    Abdom Imaging; 2002; 27(2):129-38. PubMed ID: 11847572
    [No Abstract]   [Full Text] [Related]  

  • 13. [Vascularization patterns in focal liver lesions: comparison of plain and signal-enhanced amplitude-modulated color duplex ultrasonography].
    Hosten N; Steger W; Bechstein WO; Zendel WJ; Venz S; Lemke AJ; Weber S; Vogl TJ; Felix R
    Rofo; 1997 Jun; 166(6):507-13. PubMed ID: 9273003
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Contrast enhancement patterns of hepatic tumours during the vascular phase using coded harmonic imaging and Levovist to differentiate hepatocellular carcinoma from other focal lesions.
    Furuse J; Nagase M; Ishii H; Yoshino M
    Br J Radiol; 2003 Jun; 76(906):385-92. PubMed ID: 12814924
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vascularity of hepatocellular carcinoma: assessment with contrast-enhanced second-harmonic versus conventional power Doppler US.
    Choi BI; Kim TK; Han JK; Kim AY; Seong CK; Park SJ
    Radiology; 2000 Feb; 214(2):381-6. PubMed ID: 10671584
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quantitative comparison of tumor vascularity of hepatocellular carcinoma after intravenous contrast agent: conventional versus harmonic power Doppler US.
    Park SH; Kim TK; Lee KH; Kim AY; Choi JI; Han JK; Choi BI
    Abdom Imaging; 2001; 26(2):178-83. PubMed ID: 11178696
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Contrast enhanced power Doppler sonography: comparison of various administration forms of the ultrasound contrast agent Levovist].
    Kratzer W; Kächele V; Merkle E; Mason RA; Büchner M; von Tirpitz C; Pfeiffer M
    Rofo; 2000 May; 172(5):443-8. PubMed ID: 10874971
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Usefulness of contrast-enhanced ultrasonography with dynamic flow imaging to evaluate therapeutic effects for hepatocellular carcinoma.
    Hotta N; Tagaya T; Maeno T; Ishikawa T; Okumura A; Fukuzawa Y; Kakumu S
    Hepatogastroenterology; 2003; 50(54):1867-71. PubMed ID: 14696421
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization and detection of hepatocellular carcinoma (HCC): comparison of the ultrasound contrast agents SonoVue (BR 1) and Levovist (SH U 508A)--comparison of SonoVue and Levovist in HCC.
    von Herbay A; Haeussinger D; Gregor M; Vogt C
    Ultraschall Med; 2007 Apr; 28(2):168-75. PubMed ID: 17447216
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Microbubble disappearance-time is the appropriate timing for liver-specific imaging after injection of Levovist.
    Maruyama H; Matsutani S; Okugawa H; Kobayashi S; Yoshizumi H; Ebara M; Saisho H
    Ultrasound Med Biol; 2006 Dec; 32(12):1809-15. PubMed ID: 17169692
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.